Cytokinetics, Incorporated — Q3 2016 Form 10-Q
Reporting period: Quarter and nine months ended September 30, 2016. Cytokinetics is a late-stage biopharmaceutical company developing muscle-function therapies; it has no commercial product sales. Amounts below are USD millions unless otherwise stated.
Financial performance and liquidity
| Metric | Q3 2016 | Q3 2015 | Nine months 2016 | Nine months 2015 |
|---|---|---|---|---|
| Revenue | $59.0 | $7.9 | $73.3 | $18.9 |
| Research and development expense | $19.3 | $11.6 | $42.6 | $33.1 |
| General and administrative expense | $7.2 | $5.3 | $21.1 | $14.1 |
| Operating income (loss) | $32.5 | $(8.9) | $9.5 | $(28.4) |
| Net income (loss) | $31.9 | $(8.8) | $7.8 | $(28.3) |
| Diluted earnings (loss) per share | $0.74 | $(0.23) | $0.19 | $(0.73) |
- Revenue quality: Q3 and nine-month results included $50.0 million of license revenue recognized under the September 2016 Astellas amendment. The company’s revenue is collaboration- and milestone-dependent, not product sales.
- Cash flow: Nine-month operating cash use was $40.8 million, versus $14.8 million provided in the prior-year period. Cash and cash equivalents fell to $30.3 million from $65.1 million at year-end 2015.
- Liquidity: Cash, cash equivalents and investments totaled $86.3 million at September 30, down from $111.6 million at December 31, 2015. Management believed resources would fund operations for at least 12 months, while warning that continued losses and cash outflows are expected.
- Balance sheet and debt: Total assets were $158.2 million; total liabilities, $74.9 million; and stockholders’ equity, $83.3 million. Long-term debt had a $30.0 million gross principal balance and $29.7 million carrying value, bearing 7.5% stated interest and a 9.3% effective rate. Repayment is scheduled in installments beginning October 2017, with maturity in October 2020. An additional $10 million borrowing was conditionally available through March 2017.
Material changes and operating developments
- Revenue increased sharply year over year, principally because the Astellas amendment generated $50.0 million of Q3 license revenue. Related-party accounts receivable were $67.0 million at quarter-end; the filing says $65.0 million was received from Astellas in October.
- Operating expenses rose: nine-month R&D increased $9.4 million, primarily reflecting clinical costs and personnel, while G&A increased $7.0 million, including personnel, outsourced services and legal costs.
- VITALITY-ALS, the Phase 3 tirasemtiv trial, completed enrollment with more than 700 patients. Its data monitoring committee recommended continuing without protocol changes. The filing does not provide trial results.
- Astellas’ July amendment expanded collaboration on CK-2127107 in ALS and granted Astellas an option to collaborate on tirasemtiv. Cytokinetics recognized the $50.0 million amendment fee and accelerated milestone as license revenue. A separate $15.0 million tirasemtiv option fee was received in October and deferred pending option exercise or expiry.
- Amgen decided to advance omecamtiv mecarbil into Phase 3, with a cardiovascular outcomes trial expected to start in Q4 2016. Servier exercised its option to commercialize the drug in Europe and specified CIS countries, including Russia.
Outlook, risks and unusual items
- Management expected R&D and G&A expenses to increase significantly in 2016 compared with 2015; no specific expense or revenue guidance figures are provided in the supplied filing text.
- The company expected ongoing operating losses and cash outflows and noted it may need additional collaboration funding, equity or debt financing. If funding is unavailable on acceptable terms, programs could be delayed, reduced or discontinued.
- Key clinical and regulatory risks include the uncertain safety and efficacy of drug candidates, trial timing and enrollment, and whether regulators will accept slow vital capacity as a sufficient endpoint for tirasemtiv in ALS. The filing also notes prior tirasemtiv Phase 2b failure to meet its primary endpoint.
- Development depends materially on partners’ decisions: Amgen controls omecamtiv mecarbil development, and Astellas controls much of CK-2127107 development. The company bears tirasemtiv development costs during Astellas’ option period; CK-2127107 ALS costs may also create future co-funding obligations.
- The $4.5 million settlement with the BENEFIT-ALS contract research organization was recorded as a reduction of R&D expense in June 2016 and received in July. The dispute was resolved with no admission of liability.
- Debt is secured by substantially all current and future assets other than intellectual property and includes restrictive covenants and events of default. The final potential $10 million draw depends on specified conditions.
Important facts for investors to verify
- Whether the $65 million Astellas receivable noted as collected in October was received in full and how the remaining quarter-end receivable was settled.
- VITALITY-ALS results, timing of their release, and regulatory feedback on trial endpoints and whether additional trials may be required.
- Astellas’ decision on the tirasemtiv option, related payments, and potential effects on development funding and territorial rights.
- Omecamtiv mecarbil Phase 3 trial initiation and Astellas’ CK-2127107 clinical progress and future cost-sharing requirements.
- Cash runway assumptions, cash burn, and access to additional financing, including the conditions attached to the remaining loan capacity.